Literature DB >> 1957557

Prolactinoma and body weight: a retrospective study.

L B Creemers1, P M Zelissen, J W van 't Verlaat, H P Koppeschaar.   

Abstract

Body weight and weight history in association with hormone levels were studied retrospectively in 47 patients with prolactinoma; macroprolactinoma was diagnosed in 36, microprolactinoma in 11 patients. At the time of diagnosis a weight history could be traced in 14 patients, 9 patients having gained weight (11.8 +/- 2 kg), 1 with a weight loss of 5 kg, and 4 reporting unaltered body weight. Body weight and Body Mass Index before treatment were 83 +/- 2.4 kg and 27.3 +/- 0.6 kg/m2, respectively. In the male patients the prevalence of BMI greater than or equal to 25 was greater than in the average Dutch male population (p less than 0.001). After 6 months of treatment, mainly with bromocriptine, patients with macroprolactinoma had lost 5.5 +/- 1.6% (p less than 0.002) of initial body weight. No significant weight change occurred in patients with microprolactinoma. Weight loss did not correlate with degree of hyperprolactinemia, nor with decrease of prolactin levels during treatment, in either group of patients. Thyroid or gonadal function were not associated with weight loss either. It appears that prolactinoma is associated with a higher frequency of overweight, as far as patients with macroprolactinoma are concerned.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1957557     DOI: 10.1530/acta.0.1250392

Source DB:  PubMed          Journal:  Acta Endocrinol (Copenh)        ISSN: 0001-5598


  15 in total

1.  Randomized pilot study of cabergoline, a dopamine receptor agonist: effects on body weight and glucose tolerance in obese adults.

Authors:  C D Gibson; W Karmally; D J McMahon; S L Wardlaw; J Korner
Journal:  Diabetes Obes Metab       Date:  2011-12-27       Impact factor: 6.577

2.  Long-term efficacy of bromocriptine in macroprolactinomas and giant prolactinomas in men.

Authors:  Arijit Chattopadhyay; Anil Bhansali; Shariq R Masoodi
Journal:  Pituitary       Date:  2005       Impact factor: 4.107

3.  Low prolactin levels are associated with visceral adipocyte hypertrophy and insulin resistance in humans.

Authors:  Antonio J Ponce; Tomás Galván-Salas; Ricardo M Lerma-Alvarado; Xarubet Ruiz-Herrera; Tomás Hernández-Cortés; Rodrigo Valencia-Jiménez; Laura E Cárdenas-Rodríguez; Gonzalo Martínez de la Escalera; Carmen Clapp; Yazmín Macotela
Journal:  Endocrine       Date:  2020-01-09       Impact factor: 3.633

4.  Hyperprolactinemia has no effect on plasma ghrelin levels in patients with prolactinoma.

Authors:  Tuncay Delibaşı; Müyesser Sayki Arslan; Erman Çakal; Mustafa Şahin; Oya Topaloğlu; Esra Tutal; İlknur Öztürk Ünsal; Başak Karbek; Bekir Uçan; Aşkın Güngüneş; Melia Karaköse; Mustafa Çalışkan; Taner Demirci; Gülfer Tabur; Mustafa Özbek
Journal:  J Turk Ger Gynecol Assoc       Date:  2015-06-01

Review 5.  Prolactin and human weight disturbances: A puzzling and neglected association.

Authors:  Luis G Sobrinho; Nelson D Horseman
Journal:  Rev Endocr Metab Disord       Date:  2019-06       Impact factor: 6.514

6.  Evaluation of body weight, insulin resistance, leptin and adiponectin levels in premenopausal women with hyperprolactinemia.

Authors:  Aysegul Atmaca; Birsen Bilgici; Gulcin Cengiz Ecemis; Ozgur Korhan Tuncel
Journal:  Endocrine       Date:  2013-03-26       Impact factor: 3.633

7.  Evaluation of insulin sensitivity in hyperprolactinemic subjects by euglycemic hyperinsulinemic clamp technique.

Authors:  Alpaslan Tuzcu; Serkan Yalaki; Senay Arikan; Deniz Gokalp; Mithat Bahcec; Sadiye Tuzcu
Journal:  Pituitary       Date:  2009-05-01       Impact factor: 4.107

Review 8.  The effects of hyperprolactinemia on bone and fat.

Authors:  Amal Shibli-Rahhal; Janet Schlechte
Journal:  Pituitary       Date:  2009       Impact factor: 4.107

9.  Prevalence of obstructive sleep apnea in patients with prolactinoma before and after treatment with dopamine agonists.

Authors:  Flávia Regina Pinho Barbosa; Cintia Marques dos Santos Silva; Giovanna Aparecida Balarini Lima; Giovanna Aparecida Balarinni Lima; Leila Warszawski; Romeu Cortes Domingues; Michele Dominic; Rosita Fontes; Leonardo Vieira Neto; Mônica Roberto Gadelha
Journal:  Pituitary       Date:  2014-10       Impact factor: 4.107

Review 10.  60 YEARS OF NEUROENDOCRINOLOGY: The hypothalamo-prolactin axis.

Authors:  David R Grattan
Journal:  J Endocrinol       Date:  2015-06-22       Impact factor: 4.286

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.